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A B S T R A C T
Human papillomavirus virus-like particles (HPV VLPs) have distinctive immunogenic properties that
generate a durable antibody response, producing high-quality neutralizing antibodies. By vaccination,
i.e., intramuscular injection of these HPV VLPs, the viral survival strategy of avoiding exposure to the
systemic immune system is completely overruled, and large amounts of vaccine-induced systemic
antibodies are generated. These systemic circulating antibodies are easily transuded to the genital
mucosa and are detectable in female genital secretions. It is well accepted that these antibodies interact
with the virions presented by an infected partner and inhibit infection. However, much less attention has
been paid to the role of anti-HPV vaccine-induced antibodies in an HPV-infected individual where
infectious virions are encountered by neutralizing antibodies in mucosal secretions. There is a clear need
to further investigate and document this role. Indeed, if HPV vaccination of HPV-infected women has an
effect on HPV transmission, auto-inoculation, and relapse after treatment, this may influence how we
model, assess, and implement HPV vaccination programmes.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The impact of human papillomavirus (HPV) vaccination,
provided sufficient vaccination coverage is reached, has been
overwhelming. Important decreases in the prevalence of detect-
able HPV DNA and genital warts have been reported in vaccinees,
as well as in unvaccinated individuals, regardless of sex, through
herd protection (Cameron et al., 2016; Drolet et al., 2015). A rapid
and significant decline in genital warts over time has also occurred
in boys and men younger than 30 years of age in population
programmes of female-only vaccination (quadrivalent vaccine)
reaching vaccination coverage over 50% (Drolet et al., 2015).
To better understand the potential impact of HPV vaccination, it
is important to recognize that HPV and its mode of infection have
particular characteristics that shape the host immune response
and permit vaccine-induced antibodies to counter the infection.* Corresponding author.
E-mail address: alex.vorsters@uantwerpen.be (A. Vorsters).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A unique combination of potent antigens and a susceptible
immune ignored virus
First, HPV viral-like particles (VLPs) have distinctive antigenic
properties. In fact, B-cell receptors interact with the dense,
optimally spaced, and repetitive protein arrays on the surface of
the VLPs, which promote the induction of an exceptionally potent
antibody response. Indeed, the oligomerization of B-cell receptor/
VLP signalling complexes leads to robust activation and prolifera-
tion signals, high levels of antibodies with high avidity, and long-
lived plasma cells that continuously produce antibodies for many
years after vaccination (Gomes et al., 2017). Interestingly, this
potent antibody response underpins the ongoing randomized
trials of single-dose schedules (Kreimer et al., 2018).
Second, HPVs have evolved to maintain immune ignorance
rather than develop mechanisms to actively counter the mucosal
and systemic immune system (Schwarz and Leo, 2008; Roden and
Stern, 2018). Fortunately, injection of the parental VLPs, as is done
when vaccinating, overcomes this immune system evasion
strategy. In fact, HPV vaccination generates 10- to 100-fold higher
levels of L1-specific serum neutralizing antibodies than a natural
infection (Stanley, 2010).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the protection against HPV infection. This has been elegantly
shown in animal models. Passive immunization, injecting sera
from 4vHPV immunized mice interperitoneally, conferred neu-
tralizing protection in mice genitally challenged with pseudovi-
rions (PsVs) (Longet et al., 2011). It is important to mention that
anti-HPV IgG antibodies were also detected at the mucosal level,
demonstrating the transudation of IgG.
Neutralizing antibodies play a crucial role
The current understanding of antibody-mediated protection is
built on the major role of neutralizing antibodies, and different
potentially complementary mechanisms have been postulated
(Stanley, 2010). For virions to access the basal mucosal cells,
epithelial microlesions are required. It has been proposed that
virions are neutralized by systemic neutralizing antibodies that
exude from these microlesions and scavenge the mucosal
membrane. As internalization is a relatively slow process that
requires a series of conformational changes, there is sufficient time
for vaccine-induced antibodies to interact with the virions and
disrupt this process. However, vaccine-induced antibodies present
at the mucosal level, which are also transudated, most likely via
interaction with the neonatal Fc receptor, may play a major role
(Schwarz, 2009; Einstein et al., 2011; Stanley et al., 2006; Li et al.,
2011). Previous studies have shown that the genital mucosa of
vaccinated girls also harbours detectable vaccine-induced tran-
suded IgG, and moderate to high correlation coefficients between
serum and cervical IgG titres have been reported (Schwarz et al.,
2009). Scherpenisse et al. reported transudated anti-HPV IgG
antibody concentrations in cervicovaginal samples of up to 2% of
the concentration detected in serum (Scherpenisse et al., 2013).
This finding indicates that we may have, solely by transudation,
anti-HPV antibodies at ‘neutralizing’ concentrations. Indeed,
Longet et al. reported in their animal model that serum antibody
levels >100-fold lower than those detectable by in vitro PsV
neutralization assays are sufficient to confer protection against an
HPV PsV genital infection (Longet et al., 2011). The neutralizing
capacity of cervicovaginal lavage samples from immunized non-
human primates has also been demonstrated in an HPV-11 athymic
mouse xenograft neutralization assay (Lowe et al., 1997). It is
important to add that levels of detectable vaccine-induced
cervicovaginal antibodies vary across the menstrual cycle (Nar-
delli-Haefliger et al., 2003). The potential impact of this variation
on protection and prevention of transmission should be taken into
account in future research.
HPV vaccination of HPV-infected women is equally
immunogenic and completely safe
It has been shown that HPV vaccination of previously HPV-
infected women is safe and generates a high-level immune
response (Arbyn et al., 2018; Group FIS, 2007; Haupt et al., 2011;
Meites et al., 2019). Therefore, even in women with a productive
infection, vaccination will lead to a potentially neutralizing
amount of transudated anti-HPV antibodies in their cervicovaginal
secretions. Furthermore, protection against non-prevalent HPV
types included in the vaccine is activated as in HPV-naïve women.
First, this concept suggests that vaccination may prevent
infectious virions from a productive infection spreading from sites
with low potential for malignant progression to the cervical
transformation zone with higher potential for progression (Schiller
and Davies, 2004). Second, vaccination may also decrease the
likelihood that women with a productive infection transmit
the infection to their sexual partner, as already postulated by
Schiller et al. in 2004 (Schiller and Davies, 2004). Indeed, inHPV-vaccinated women, newly produced viral particles are shed in
a milieu with highly potent anti-HPV antibodies that are able to
interact with and neutralize the viral particles. This finding may
imply that HPV-infected HPV-vaccinated women will no longer
(or to a lesser extent) be able to re-infect themselves or transmit
their infection(s). A special discussion of transmission interruption
could be initiated in relation to the high-risk groups for
transmission, e.g. commercial sex workers, currently outside of
any special vaccination programmes (Schim van der Loeff et al.,
2019).
Paradoxically, during follow-up of women with an existing
infection in randomized controlled vaccine trials (RCTs), no impact
of vaccination on the rate of progression was shown. However, it
should be noted that these trials were not designed to demonstrate
the potential impact of vaccination on auto-inoculation. In most
RCTs, cervical sampling occurred prior to vaccination, which as we
discuss below, may impact the risk of acquisition and perhaps the
natural course of the infection. In addition, HPV DNA assays with a
defined clinical cut-off will predominantly identify women who
already have a clinical lesion that is not affected by vaccination.
Although it remains difficult to investigate experimentally or
epidemiologically whether vaccination does block transmission,
further efforts are needed. For instance, including self-collected
none invasive cervicovaginal secretion sampling and using sensi-
tive analytical assays in the design of future vaccine trials may help
to further investigate what is happening at the level of the genital
mucosa.
The potential impact of vaccination on HPV transmission will
likely be more prominent in women than in men; viral particles are
less likely to come into contact with mucosal transduced
antibodies in men.
Potential benefit of HPV vaccination when screening
HPV-positive women
Cervical screening is a major tool contributing to the early
detection and subsequent removal of precancerous lesions.
However, the collection of cervical cells from women with a
productive genital HPV infection could also create new infection
sites for circulating infectious virions in the genital tract. Indeed,
the principle of a cytobrush is to remove epithelial cells and
consequently create microlesions, which in turn provide passage
for HPV to infect mucosal basal cells. Of note, in the animal model
mentioned above, cytobrushes were also used to create effective
entry sites for pseudovirions (Roberts et al., 2007). The more direct
and compelling study of Roberts et al. in macaques confirms the
hypothesis that cytology screening in women might lead to a
transient enhancement of susceptibility to HPV infection (Roberts
et al., 2011). Currently, the impact of screening on auto-inoculation
is unknown, so further research on this topic is merited. In this
context, vaccination of young women prior to cervical cancer
screening may be beneficial in addition to the well-established
advantage of vaccinating prior to sexual debut.
It is recognized that these biologically plausible hypotheses
warrant further proof. However, if confirmed, these may have a
substantial impact on how we model, assess, and implement HPV
vaccination programmes more effectively.
Most vaccine impact models disregard vaccinating adult
women because type-specific HPV exposure is likely to have
occurred and the benefits to the individual are seen as marginal.
However, if the hypothesis above is true, vaccination of HPV-
infected women will not only reduce auto-inoculation but also
offer additional protection to the group (herd protection) by
neutralizing the infectious virions being shed. Asymptomatic
individuals with productive lesions shedding infectious viral
particles are the main source for spreading the infection in the
112 A. Vorsters et al. / International Journal of Infectious Diseases 88 (2019) 110–112population. Therefore, strategies that potentially reduce this
transmission must be explored to accelerate the reduction in
infection. The change to primary HPV DNA screening will identify
HPV DNA-positive women who have no or only low-grade lesions
(approximately 5–10%), for whom current treatment is not
recommended.
Clearly, from this perspective, the indication for vaccination
would benefit from expanding the target population, including
HPV-positive women identified at screening (in addition to the
conventional high-risk groups) and eventually include a broader
age range in primary vaccination campaigns (Bosch et al., 2016). A
temporal drawback in this proposal reflects that in the current
global context of ongoing vaccine shortage, and the big disparity
between high income and low and middle income countries, other
strategies instead of extending the target group for vaccination
may provide a much bigger global public health benefit. However,
the better we understand the potential of HPV vaccination, the
better we can make informed decisions.
Vaccination reduces the risk of clinical disease relapse after
treatment
The first evidence that HPV vaccination also reduces post-
treatment relapse is becoming available. As well as the previous
clinical observations of Kang et al., Ghelardi et al. showed that post-
treatment vaccination of women resulted in an 81.2% (95%
confidence interval 34.3–95.7%) risk reduction of clinical disease
relapse (Ghelardi et al., 2018; Kang et al., 2013). These observations
are an additional argument for vaccination of HPV-positive
women, as they show an additional individual benefit in the case
of disease progression.
Conclusions
Based on the discussion above, we would like to call for further
investigation and documentation of the potential public health
benefits of vaccination of HPV-positive women. For modellers, these
data would provide an additional effect that should be considered
when designing HPV vaccination impact models exploring and
quantifying the herd protection observed in population pro-
grammes. Finally, these additional modes of protection may also
reduce the existing reluctance to vaccinate (young) women post-
sexual debut or known high-risk groups such as sex workers.
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